Free Access
Med Sci (Paris)
Volume 29, Number 2, Février 2013
Page(s) 139 - 141
Section Nouvelles
Published online 28 February 2013
  1. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997 ; 20 : 95–115. [CrossRef] [PubMed] [Google Scholar]
  2. Fahn S. How do you treat motor complications in Parkinson’s disease: medicine, surgery, or both? Ann Neurol 2008 ; 64 : S56–S64. [CrossRef] [PubMed] [Google Scholar]
  3. Guigoni C, Doudnikoff E, Li Q, et al. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 2007 ; 26 : 452–463. [CrossRef] [PubMed] [Google Scholar]
  4. Berthet A, Porras G, Doudnikoff E, et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 2009 ; 29 : 4829–4835. [CrossRef] [PubMed] [Google Scholar]
  5. Bezard E, Gross CE, Qin L, et al. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis 2005 ; 18 : 323–335. [CrossRef] [PubMed] [Google Scholar]
  6. Ahmed MR, Berthet A, Bychkov E, et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson’s disease. Sci Transl Med 2010 ; 2 : 28ra28. [CrossRef] [PubMed] [Google Scholar]
  7. Hallett PJ, Dunah AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Neuropharmacology 2005 ; 48 : 503–516. [CrossRef] [PubMed] [Google Scholar]
  8. Gardoni F, Polli F, Cattabeni F, Di Luc M. Calcium-calmodulin-dependent protein kinase II phosphorylation modulates PSD-95 binding to NMDA receptors. Eur J Neurosci 2006 ; 24 : 2694–2704. [CrossRef] [PubMed] [Google Scholar]
  9. Silverdale MA, Kobylecki C, Hallett PJ, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010 ; 64 : 177–180. [CrossRef] [PubMed] [Google Scholar]
  10. Fiorentini C, Gardoni F, Spano P, et al. Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem 2003 ; 278 : 20196–20202. [CrossRef] [PubMed] [Google Scholar]
  11. Yao WD, Spealman, R.D, Zhang J. Dopaminergic signaling in dendritic spines. Biochem Pharmacol 2008 ; 75 : 2055–2069. [CrossRef] [PubMed] [Google Scholar]
  12. Zhang J, Xu TX, Hallett PJ, et al. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci 2009 ; 29 : 2948–2960. [CrossRef] [PubMed] [Google Scholar]
  13. Nash JE, Johnston TH, Collingridge GL, et al. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson’s disease and L-DOPA-induced dyskinesia. FASEB J 2005 ; 19 : 583–585. [PubMed] [Google Scholar]
  14. Porras G, Berthet A, Dehay B, et al. PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 2012 ; 122 : 3977–3989. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.